Literature DB >> 24678596

Riluzole effects on behavioral sensitivity and the development of axonal damage and spinal modifications that occur after painful nerve root compression.

Kristen J Nicholson1, Sijia Zhang, Taylor M Gilliland, Beth A Winkelstein.   

Abstract

OBJECT: Cervical radiculopathy is often attributed to cervical nerve root injury, which induces extensive degeneration and reduced axonal flow in primary afferents. Riluzole inhibits neuro-excitotoxicity in animal models of neural injury. The authors undertook this study to evaluate the antinociceptive and neuroprotective properties of riluzole in a rat model of painful nerve root compression.
METHODS: A single dose of riluzole (3 mg/kg) was administered intraperitoneally at Day 1 after a painful nerve root injury. Mechanical allodynia and thermal hyperalgesia were evaluated for 7 days after injury. At Day 7, the spinal cord at the C-7 level and the adjacent nerve roots were harvested from a subgroup of rats for immunohistochemical evaluation. Nerve roots were labeled for NF200, CGRP, and IB4 to assess the morphology of myelinated, peptidergic, and nonpeptidergic axons, respectively. Spinal cord sections were labeled for the neuropeptide CGRP and the glutamate transporter GLT-1 to evaluate their expression in the dorsal horn. In a separate group of rats, electrophysiological recordings were made in the dorsal horn. Evoked action potentials were identified by recording extracellular potentials while applying mechanical stimuli to the forepaw.
RESULTS: Even though riluzole was administered after the onset of behavioral sensitivity at Day 1, its administration resulted in immediate resolution of mechanical allodynia and thermal hyperalgesia (p < 0.045), and these effects were maintained for the study duration. At Day 7, axons labeled for NF200, CGRP, and IB4 in the compressed roots of animals that received riluzole treatment exhibited fewer axonal swellings than those from untreated animals. Riluzole also mitigated changes in the spinal distribution of CGRP and GLT-1 expression that is induced by a painful root compression, returning the spinal expression of both to sham levels. Riluzole also reduced neuronal excitability in the dorsal horn that normally develops by Day 7. The frequency of neuronal firing significantly increased (p < 0.045) after painful root compression, but riluzole treatment maintained neuronal firing at sham levels.
CONCLUSIONS: These findings suggest that early administration of riluzole is sufficient to mitigate nerve root-mediated pain by preventing development of neuronal dysfunction in the nerve root and the spinal cord.

Entities:  

Keywords:  CGRP = calcitonin gene–related peptide; GLT-1; HSD = honestly significant difference; IB4 = isolectin-B4; LTM = low-threshold mechanoreceptive; NF200 = neurofilament-200; ROI = region of interest; WDR = wide dynamic range; injury; nerve root; neuronal hyperexcitability; pain; radiculopathy; riluzole; spinal cord injury

Mesh:

Substances:

Year:  2014        PMID: 24678596     DOI: 10.3171/2014.2.SPINE13672

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  9 in total

1.  Use of the Rat Grimace Scale to Evaluate Neuropathic Pain in a Model of Cervical Radiculopathy.

Authors:  Blythe H Philips; Christine L Weisshaar; Beth A Winkelstein
Journal:  Comp Med       Date:  2017-02-01       Impact factor: 0.982

2.  Pre-treatment with Meloxicam Prevents the Spinal Inflammation and Oxidative Stress in DRG Neurons that Accompany Painful Cervical Radiculopathy.

Authors:  Sonia Kartha; Christine L Weisshaar; Blythe H Philips; Beth A Winkelstein
Journal:  Neuroscience       Date:  2018-08-04       Impact factor: 3.590

3.  Pain from intra-articular NGF or joint injury in the rat requires contributions from peptidergic joint afferents.

Authors:  Jeffrey V Kras; Christine L Weisshaar; Parul S Pall; Beth A Winkelstein
Journal:  Neurosci Lett       Date:  2015-08-01       Impact factor: 3.046

4.  Superoxide Dismutase-Loaded Porous Polymersomes as Highly Efficient Antioxidants for Treating Neuropathic Pain.

Authors:  Sonia Kartha; Lesan Yan; Christine L Weisshaar; Meagan E Ita; Vladimir V Shuvaev; Vladimir R Muzykantov; Andrew Tsourkas; Beth A Winkelstein; Zhiliang Cheng
Journal:  Adv Healthc Mater       Date:  2017-07-03       Impact factor: 9.933

5.  Changes in Neuronal Activity in the Anterior Cingulate Cortex and Primary Somatosensory Cortex With Nonlinear Burst and Tonic Spinal Cord Stimulation.

Authors:  Julia C Quindlen-Hotek; Alexander R Kent; Patrisia De Anda; Sonia Kartha; Alexander M Benison; Beth A Winkelstein
Journal:  Neuromodulation       Date:  2020-02-06

6.  Riluzole induces LTD of spinal nociceptive signaling via postsynaptic GluR2 receptors.

Authors:  Xiao Zhang; Yandong Gao; Qun Wang; Shibin Du; Xiaolan He; Nan Gu; Yan Lu
Journal:  J Pain Res       Date:  2018-10-26       Impact factor: 3.133

7.  Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.

Authors:  Nicolas Kerckhove; Jérome Busserolles; Trevor Stanbury; Bruno Pereira; Valérie Plence; Franck Bonnetain; Ivan Krakowski; Alain Eschalier; Denis Pezet; David Balayssac
Journal:  BMJ Open       Date:  2019-06-09       Impact factor: 2.692

8.  Inhibiting spinal secretory phospholipase A2 after painful nerve root injury attenuates established pain and spinal neuronal hyperexcitability by altering spinal glutamatergic signaling.

Authors:  Sonia Kartha; Prabesh Ghimire; Beth A Winkelstein
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

9.  Local Riluzole Release from a Thermosensitive Hydrogel Rescues Injured Motoneurons through Nerve Root Stumps in a Brachial Plexus Injury Rat Model.

Authors:  Jintao Fang; Liang Li; Hong Zhai; Bengang Qin; Daping Quan; Enxian Shi; Menghai Zhu; Jiantao Yang; Xiaolin Liu; Liqiang Gu
Journal:  Neurochem Res       Date:  2020-09-28       Impact factor: 3.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.